Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Praxis Precision Medicines ( (PRAX) ) just unveiled an update.
On January 6, 2026, Praxis Precision Medicines entered into an underwriting agreement with a syndicate of banks for an underwritten public offering of 2,212,000 shares of common stock at $260 per share, with closing expected on January 8, 2026, and the underwriters fully exercising their option on January 7, 2026, to purchase an additional 331,800 shares. The company expects to raise approximately $621.2 million in net proceeds, which it plans to use, together with existing cash, equivalents and marketable securities, to fund commercialization preparation for late-stage candidates, continue clinical and early-stage R&D, and cover working capital and general corporate needs, and believes this capital should support its operating and capital expenditure requirements into 2028, potentially strengthening its financial position and funding visibility for stakeholders.
The most recent analyst rating on (PRAX) stock is a Buy with a $843.00 price target. To see the full list of analyst forecasts on Praxis Precision Medicines stock, see the PRAX Stock Forecast page.
Spark’s Take on PRAX Stock
According to Spark, TipRanks’ AI Analyst, PRAX is a Neutral.
The score is held back primarily by very weak financial performance (large losses and worsening negative free cash flow). Offsetting this are strong bullish technical momentum (price above key moving averages with positive MACD) and notably positive corporate catalysts (Breakthrough Therapy Designation and positive Phase 3 results with NDA planning). Valuation is limited by negative earnings and no dividend.
To see Spark’s full report on PRAX stock, click here.
More about Praxis Precision Medicines
Praxis Precision Medicines, Inc. is a biopharmaceutical company focused on developing late-stage, clinical-stage and earlier-stage product candidates, with an emphasis on preparing for potential commercialization of its most advanced programs while continuing research and development across its broader pipeline.
Average Trading Volume: 1,076,358
Technical Sentiment Signal: Buy
Current Market Cap: $6.92B
For an in-depth examination of PRAX stock, go to TipRanks’ Overview page.